01 October 2010
The divergent clinical presentations of transfusion-related acute lung injury illustrated by two case reports
Alexander P.J. VlaarABCDEF, Leendert PorcelijnBCDE, Ingeborgh H.M. van Rooijen-SchreursBE, Neubury Maxton LardyBCDE, Marie Jose KerstenBDE, Nicole P. JuffermansABCDEFMed Sci Monit 2010; 16(10): CS129-134 :: ID: 881185
Abstract
Background: Although the 2-event pathogenesis of transfusion-related (TR) acute lung injury (ALI) has been accepted as an explanatory model, case reports classically describe patients without other risk factors for ALI. Patients who exhibit another risk factor for the onset of ALI may be neglected as having TRALI, which contributes to underreporting.
Case Report: Two cases of TRALI are reported. The first case is a patient with a hematologic malignancy who experienced ALI within 1 hour after a transfusion of concentrated platelets (PLT), with no other risk factor for ALI present. The second case is a patient with severe sepsis with multiorgan failure who received multiple transfusions during a laparotomy and exhibited ALI perioperatively. The implicated blood components originated from female donors in both cases. Analysis of the plasma of the PLT donor in the first case revealed HLA class I and II antibodies directed against the patient’s antigen. Analysis of the plasma of the fresh-frozen plasma donor in the second case did not reveal antibodies using the techniques available at that time. However, after involvement of this donor in a TRALI reaction in another recipient, HLA II antibodies directed against the antigen of the recipient were detected in the newly available single antigen Luminex technique.
Conclusions: The 2 cases illustrate that TRALI can occur both in the absence and in the presence of another ALI risk factor. Awareness should be increased that all patients exhibiting ALI within 6 hours of a blood transfusion, including possible TRALI, should be reported to the blood bank.
Keywords: perioperative period, Plasma - immunology, HLA Antigens - immunology, Blood Transfusion - adverse effects, Blood Donors, Antibodies - immunology, Acute Lung Injury - physiopathology, Platelet Transfusion - adverse effects, Risk Factors, Time Factors
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952